[{"from": "human", "value": "Provide a description of this molecule. [C][C][S][=Branch1][C][=O][=Branch1][C][=O][N][C][C][Branch1][Ring2][C][Ring1][Ring2][Branch1][Ring2][C][C][#N][N][C][=C][Branch1][Branch1][C][=N][Ring1][Branch1][C][=C][C][=C][N][C][Ring1][Branch1][=N][C][=N][Ring1][=Branch2]"}, {"from": "gpt", "value": "The molecule is a pyrrolopyrimidine that is 7H-pyrrolo[2,3-d]pyrimidine substituted by a 1-[3-(cyanomethyl)-1-(ethanesulfonyl)azetidin-3-yl]-1H-pyrazol-4-yl group at position 5. It is an FDA approved selective Janus Kinase 1 and 2 (JAK1 and JAK2) inhibitor used for the treatment of rheumatoid arthritis. It has a role as an antirheumatic drug, an EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor, an anti-inflammatory agent, an immunosuppressive agent and an antiviral agent. It is a pyrrolopyrimidine, a member of pyrazoles, a member of azetidines, a sulfonamide and a nitrile."}]